This morning, Argenx announced positive topline results from the Phase III ALKIVIA trial of Vyvgart in Myositis, which met its primary endpoint on the overall population, delivering a 15.4-point improvement in mean TIS at Week 52 (47.95 vs 32.56; p=0.0011). More importantly, given Argenx plans to file these results by subtype, the IMNM subgroup saw a statistically significant benefit (p=0.0048) at a 14.8-point improvement (45.05 vs 30.24), whereas while the magnitude of the benefit was consistent across DM ...